LIR-1 or NKG2A blockade resulted in increased NK cell cytotoxicity against AML, suggesting that the cocktail consisting of anti-KIR, anti-LIR-1 and anti-NKG2A antibodies may be a necessary option for better efficacy [166, 167]. The gene discussed is LILRB1; the disease is acute myeloid leukemia.